Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adicet Bio, Inc. (ACET)

19.26   0.68 (3.66%) 12-02 16:00
Open: 18.37 Pre. Close: 18.58
High: 19.29 Low: 18.01
Volume: 467,646 Market Cap: 825(M)

Technical analysis

as of: 2022-12-02 4:20:38 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 25.54     One year: 29.83
Support: Support1: 18.21    Support2: 15.96
Resistance: Resistance1: 21.87    Resistance2: 25.54
Pivot: 18.28
Moving Average: MA(5): 18.09     MA(20): 18.54
MA(100): 16.41     MA(250): 15.16
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 45.9     %D(3): 36.7
RSI: RSI(14): 58.7
52-week: High: 21.87  Low: 9.88
Average Vol(K): 3-Month: 601 (K)  10-Days: 597 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ACET ] has closed below upper band by 32.6%. Bollinger Bands are 33.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 19.29 - 19.36 19.36 - 19.42
Low: 17.82 - 17.91 17.91 - 17.98
Close: 19.12 - 19.24 19.24 - 19.35

Company Description

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Headline News

Tue, 29 Nov 2022
Wall Street Analysts Think Adicet Bio, Inc. (ACET) Could Surge 72%: Read This Before Placing a Bet - Nasdaq

Tue, 29 Nov 2022
Charity partnership tackles inequalities in HIV prevention in Nigeria - Charity Today News

Wed, 16 Nov 2022
Adicet Bio (NASDAQ:ACET) Shares Down 10.5% After Insider Selling - MarketBeat

Fri, 11 Nov 2022
Adicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021) - Simply Wall St

Thu, 10 Nov 2022
Is Adicet Bio Inc (ACET) Stock a Smart Value Thursday? - InvestorsObserver

Tue, 08 Nov 2022
Adicet Bio (NASDAQ:ACET) delivers shareholders stellar 106% return over 1 year, surging 16% in the last week alone - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 43 (M)
Shares Float 28 (M)
% Held by Insiders 10.5 (%)
% Held by Institutions 101.4 (%)
Shares Short 3,590 (K)
Shares Short P.Month 3,960 (K)

Stock Financials

EPS -1.05
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.42
Profit Margin (%) -183
Operating Margin (%) -188.9
Return on Assets (ttm) -11.8
Return on Equity (ttm) -20.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.22
Sales Per Share 0.71
EBITDA (p.s.) -1.3
Qtrly Earnings Growth 0
Operating Cash Flow -39 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -18.35
PEG Ratio -0.4
Price to Book value 2.59
Price to Sales 27.09
Price to Cash Flow -20.97

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-09-15
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.